https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Puma_Biotechnology_IncPuma Biotechnology Inc - Revizia istoricului2026-04-04T23:20:16ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=Puma_Biotechnology_Inc&diff=435161&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei Puma Biotechnology Inc listata cu simbolul US.PBYI ==Descriere companie== Puma Biotechnology, Inc. (https://www.pumabiotechnology.com/) is a biopharmaceutical company. The Company is focused on the development and commercialization of products to improve cancer care. The Company's products include PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357, as well as certain related compounds. Its lead product, NERLYNX, is an oral version of...2024-09-18T18:20:28Z<p>Pagină nouă: Pagina dedicata companiei Puma Biotechnology Inc listata cu simbolul US.PBYI ==Descriere companie== Puma Biotechnology, Inc. (https://www.pumabiotechnology.com/) is a biopharmaceutical company. The Company is focused on the development and commercialization of products to improve cancer care. The Company's products include PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357, as well as certain related compounds. Its lead product, NERLYNX, is an oral version of...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Puma Biotechnology Inc listata cu simbolul US.PBYI<br />
<br />
==Descriere companie==<br />
Puma Biotechnology, Inc. (https://www.pumabiotechnology.com/) is a biopharmaceutical company. The Company is focused on the development and commercialization of products to improve cancer care. The Company's products include PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357, as well as certain related compounds. Its lead product, NERLYNX, is an oral version of neratinib, which is a potent irreversible tyrosine kinase inhibitor (TKI), that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment for patients with HER2-positive metastatic breast cancer. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors. The Company has two subsidiaries: Puma Biotechnology Ltd and Puma Biotechnology, B.V.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.PBYI" /><br />
<br />
==Ultimele stiri despre Puma Biotechnology Inc (US.PBYI)==<br />
<dynamicpagelist><br />
category=US.PBYI<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.PBYI]][[Categorie:Stiri despre companii]]</div>Admin